OPKO Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 07, 2023 at 02:48 am IST
Share
OPKO Health, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 178.6 million compared to USD 179.74 million a year ago. Net loss was USD 84.47 million compared to USD 86.09 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.11 a year ago.
For the nine months, revenue was USD 681.59 million compared to USD 818.86 million a year ago. Net loss was USD 122.38 million compared to USD 243.17 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 0.34 a year ago.
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
OPKO HEALTH, INC. 
